In the lead up to what we know is a busy time for advisers, managers, and investors we have a selection of interesting articles for you in this issue on growth-focused technologies. As you will see, some of our contributors are making a strong case for continued investment in innovative technologies, homegrown R&D in the life sciencesoffering roll-out stability while we wait to see what is in store with the dreaded Brexit.
With this in mind Andrew Aldridge of Deepbridge Capital outlines the case for continuing to push the boundaries in the life sciences and Jo Oliver of Octopus Titan VCT discusses the wealth of opportunities in tech-driven areas. Brian Moretta of Hardman & Co, offers a salutary note on why advisers need to look carefully at the governance behind business relief (BR) products and Darius McDermott from Chelsea Financial Service looks back on how investor opportunities fared in 2018.
Along with our regular features on exciting new exits, and newest offerings in the sector we have a preview for you on two not-to-be-missed events in November and December. Our Open Offers section is now brought to you in partnership with GrowthInvest and you can see exactly what opportunities are currently available.
As ever, we love to get your feedback so do get in touch.
All the very best and enjoy GB Investments issue 11!
Alex
